Unmet need in PH-ILD: A clinician survey of real-world management of PH-ILD in Europe

BackgroundWith no approved therapies for pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD) in Europe, we surveyed clinician perceptions on PH-ILD management and unmet need to understand current real-world practices.Methods: An online clinician survey on PH-ILD management was conducted in France, Germany, Italy, Spain, and the UK.Results: Fifty-five clinicians (78% pulmonologists) each managing a median 20 PH-ILD patients (interquartile range [IQR]=10–50), participated. Upon PH suspicion, clinicians referred a median 50% (IQR=20–73%) of patients for echocardiography alone and 35% (IQR=20–78%) for echocardiography, followed by right heart catheterisation.Upon diagnosis, a median 20% (IQR=9–30%), 40% (IQR=20–50%) and 35% (IQR=20–55%) of patients fell under the pulmonary arterial pressure ranges of 21–24mmHg, 25–34mmHg and >35mmHg respectively. Fifty percent of patients received off-label treatment for their PH and, of those, off-label phosphodiesterase-5 inhibitor (PDE-5i), endothelin receptor antagonist (ERA) and prostacyclin analogues were prescribed first-line by 78%, 9% and 7% of clinicians, respectively. Upon PDE-5i non-response, 35% of clinicians proceed with an ERA, 35% with no further therapy. Fifty-five percent of clinicians used dual therapy. Yearly median inpatient admissions and emergency visits were 2.0 (IQR=1.3–2.9) and 1.5 (IQR=1.0–2.0) respectively (n=31 responses). Most clinicians (69%) highlighted lack of efficacy or evidence for current therapies as a key gap in PH-ILD management.ConclusionsThis study gives insight into real-world European PH-ILD diagnosis and management. With significant use of off-label treatment, there is a large unmet need due to lack of approved therapies. Despite updated guidelines, more evidence is needed to standardise PH-ILD management.